Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)

Emily K Ninmer, Gina R Petroni, Brian R Gastman, Elizabeth M Gaughan, James M Isaacs, Kathleen Haden, Varinder Kaur, Nolan A Wages, Kimberly A Chianese-Bullock, Kelly T Smith, Paul Wright, Jennifer Bryant, Marya Dunlap-Brown, Jack A Engel, Stefan Bekiranov, Ileana S Mauldin, Thach-Giao Truong, Timothy N J Bullock, Craig L Slingluff

Open source

DOI: 10.1136/jitc-2025-013613
Published: 2026-03
Container: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-013613,
  title = {Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)},
  author = {Emily K Ninmer and Gina R Petroni and Brian R Gastman and Elizabeth M Gaughan and James M Isaacs and Kathleen Haden and Varinder Kaur and Nolan A Wages and Kimberly A Chianese-Bullock and Kelly T Smith and Paul Wright and Jennifer Bryant and Marya Dunlap-Brown and Jack A Engel and Stefan Bekiranov and Ileana S Mauldin and Thach-Giao Truong and Timothy N J Bullock and Craig L Slingluff},
  year = {2026},
  journal = {Journal for ImmunoTherapy of Cancer},
  doi = {10.1136/jitc-2025-013613},
  url = {https://doi.org/10.1136/jitc-2025-013613}
}

RIS

TY  - JOUR
TI  - Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
AU  - Emily K Ninmer
AU  - Gina R Petroni
AU  - Brian R Gastman
AU  - Elizabeth M Gaughan
AU  - James M Isaacs
AU  - Kathleen Haden
AU  - Varinder Kaur
AU  - Nolan A Wages
AU  - Kimberly A Chianese-Bullock
AU  - Kelly T Smith
AU  - Paul Wright
AU  - Jennifer Bryant
AU  - Marya Dunlap-Brown
AU  - Jack A Engel
AU  - Stefan Bekiranov
AU  - Ileana S Mauldin
AU  - Thach-Giao Truong
AU  - Timothy N J Bullock
AU  - Craig L Slingluff
PY  - 2026
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2025-013613
UR  - https://doi.org/10.1136/jitc-2025-013613
ER  -

APA

Ninmer, E. K., Petroni, G. R., Gastman, B. R., Gaughan, E. M., Isaacs, J. M., Haden, K., Kaur, V., Wages, N. A., Chianese-Bullock, K. A., Smith, K. T., Wright, P., Bryant, J., Dunlap-Brown, M., Engel, J. A., Bekiranov, S., Mauldin, I. S., Truong, T., Bullock, T. N. J., & Slingluff, C. L. (2026). Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013613

Source records

crossref · retrieved 2026-09-26T22:58:59.497Z